Study characteristics
| Characteristic | Intervention group (IG_T2) | Control group (T2) |
| n=21 | n=19 | |
| Age (years) | 14.5±3.9 (15.3; 6–23) | 15.4±3.7 (17.2; 6–20) |
| BMI (kg/m2) | 20.3±4.5 (19.4; 13–33) | 20.2±3.3 (20.5; 13–26) |
| Male, n (%) | 13 (62) | 9 (47) |
| Months since diagnosis | 9.6±2.9 (9.1; 6–17) | 8.4±3.7 (6.1; 3–16) |
| Days since last inpatient ctx | 67.0±32.3 (62.0; 6–144) | 47.6±30.8 (47.0; 1–118) |
| Cancer type | ||
| ALL | 9 (43%) | 4 (21%) |
| AML | 1 (5%) | 0 (0%) |
| Lymphoma | 6 (29%) | 5 (26%) |
| EWS | 3 (14%) | 4 (21%) |
| OSS | 1 (5%) | 2 (11%) |
| Tumour location | ||
| Lower extremity | 3 (14%) | 4 (21%) |
| Upper extremity/trunk | 1 (5%) | 1 (5%) |
| Other solid tumour | 1 (5%) | 4 (21%) |
| Medical therapy | ||
| Ctx | 21 (100%) | 19 (100%) |
| Operation | 4 (19%) | 8 (42%) |
| Resection | 3 (14%) | 3 (16%) |
| Prosthesis | 1 (5%) | 4 (21%) |
| Amputation | 0 (0%) | 1 (5%) |
| Radiotherapy | 4 (19%) | 7 (37%) |
| Stem cell transplantation | 2 (10%) | 5 (26%) |
| Autologous | 0 (0%) | 2 (11%) |
| Allogeneic | 2 (10%) | 3 (16%) |
| Partially limited walking ability | 3 (14%) | 5 (26%) |
Results are given as mean±SD (median; range).
ALL, acute lymphoblastic leukaemia; AML, acute myeloic leukaemia; BMI, body mass index; ctx, chemotherapy; EWS, Ewing’s sarcoma; IG, intervention group; OSS, osteosarcoma.